Jade Biosciences, Inc. (JBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.06B
Last updated: Nov 17, 2026 at 4:10 PM ET
Jade Biosciences, Inc. (JBIO) Statistics
Jade Biosciences (JBIO) has a market cap of $1.06B and an enterprise value of $980.63M. Its share count is up 81.27% from a year earlier.
Total Valuation
Enterprise value is 7.58% below the market cap, as cash exceeds debt.
| Market Cap | $1.06B |
|---|---|
| Enterprise Value | $980.63M |
| Latest price (Nov 17, 2026) | $15.40 |
Key Dates
The next earnings report is expected on Mar 4, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 4, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 43.93% over 52 weeks and trades 1.65% above its 50-day average.
| Beta (1Y) | 1.35 |
|---|---|
| 52-Week Change | +43.93% |
| 1-Month Change | +11.35% |
| 3-Month Change | -31.71% |
| 6-Month Change | -29.62% |
| 5-Year Change | -97.48% |
| Total Return (1Y) | +43.93% |
| Total Return (3Y CAGR) | -66.50% |
| Total Return (5Y CAGR) | -47.83% |
| Return vs SPY (1Y) | +10.18% |
| Max Drawdown (1Y) | -50.06% |
| Max Drawdown (3Y) | -99.22% |
| Sharpe Ratio (1Y) | 0.29 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $15.15 |
| 200-Day Average | $18.22 |
| 52-Week Range | $11.02 to $28.00 |
| RSI (14 Days) | 51.5 |
| Average Volume (20 Days) | 885.35K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 16.03x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 16.03x |
|---|---|
| Quick Ratio | 16.03x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -43.64% and return on assets is -40.87% over the last 12 months.
| Return on Equity (ROE) | -43.64% |
|---|---|
| Return on Assets (ROA) | -40.87% |
| Return on Capital Employed (ROCE) | -43.20% |
| ROA (5Y Average) | -56.12% |
| ROIC (5Y Average) | -40.64% |
Scores
JBIO has a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 4 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$9.00K |
| Operating Income | -$196.98M |
| Pretax Income | -$198.74M |
| Net Income | -$198.77M |
| EBIT | -$197.04M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 93.65% of the $486.39M in total assets.
| Cash and Equivalents | $80.39M |
|---|---|
| Total Debt | $0 |
| Net Cash | $80.39M |
| Net Cash Per Share | $1.12 |
| Working Capital | $455.27M |
| Shareholder Equity | $455.50M |
| Book Value Per Share | $6.35 |
| Total Assets | $486.39M |
| Total Liabilities | $30.89M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$130.30M |
|---|---|
| FCF Per Share | -$2.05 |
| Depreciation and Amortization | $1.98M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
JBIO does not pay a dividend.
| Buyback Yield | -4.02% |
|---|---|
| Shareholder Yield | -4.02% |
Stock Splits
The last split was a 1-for-35 reverse split on Apr 29, 2025.
| Last Split Date | Apr 29, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:35 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About JBIO
What is JBIO's market cap?
Jade Biosciences has a market cap of $1.06B. Its enterprise value, which adds debt and subtracts cash, is $980.63M.
How many shares of JBIO are outstanding?
Jade Biosciences has 71.78M shares outstanding. The count is up 81.27% from a year earlier.
Does JBIO pay a dividend?
No. Jade Biosciences does not pay a dividend.
How much debt does JBIO have?
Jade Biosciences has $0 of total debt and $80.39M of cash and equivalents, a net cash position of $80.39M.
JBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors